Document

EX-10.1 2 a8k-93024xexhibit101.htm EX-10.1 Document

展品10.1

資產購買協議

本資產購買協議（「股東大會紀要」）協議”）自2024年9月27日起生效，並簽訂（“生效日期。和 exicure公司，一家根據特拉華州法律組建的公司（“exicure Flashpoint Therapeutics，Inc.，一個根據特拉華州法律組織成立的公司（"Flashpoint）。Exicure和Flashpoint在本聲明中也分別稱爲“方方當事人.”

陳述事項

鑑於exicure擁有或控制着與其項目相關的某些資產，包括知識產權。

鑑於Exicure希望向Flashpoint出售，並且Flashpoint希望按照本協議中規定的條款和條件收購與Exicure項目相關的Exicure資產的某些權利、所有權和利益。

因此鑑於前述前提以及雙方以下約定，並且就其他良好和有價值的考慮，特此確認收悉並且雙方一致同意如下：

第1條

定義

根據本文件，以下術語應如下解釋:

1.1“已收購的資產「」在第2.1節中有所定義。

1.2“獲取合同”在第2.1(a)節中規定的含義。

1.3“獲得的IP” 表示Exicure或其關聯公司Exicure Operating Company，即截止日期爲止所擁有的所有節目IP。

1.4“獲取的專利板塊” 意味着所獲得的知識產權內的所有專利。

1.5“行動「索賠」表示任何要求、訴訟、訴因、起訴、覈算、仲裁、調解、調查、詢問、審計、聽證會、指控、投訴、要求、通知或程序（在每種情況下，無論是合同、侵權或其他情況，無論是法律上還是在衡平法上，無論是民事還是刑事），向任何政府機關提出、由其提出、對其提出或在其面前提出。

1.6“附屬公司「個人」表示相對於任何個人，任何其他控制、被控制或與該等個人共同控制的個人，但僅限於存在此種控制時，並且「控制」是指直接或間接擁有指導實體管理或政策的權力，無論是通過(a) 擁有表決權證券、(b) 與表決權或公司治理相關的合同，(c) 直接或間接擁有超過五十 percent（50%）的受益所有權（或最大的相對更低百分比

在特定司法管轄區允許外國公司擁有該實體的投票股份資本或其他股權利益，或者其他方式。

1.7“反腐敗法律「」指美國《反海外腐敗行爲法》，經修訂的經濟合作與發展組織（OECD）關於打擊國際業務中外國公職人員賄賂的公約，以及任何其他在任何一個方或其附屬公司經營或開展業務的國家、組織或國家的可比較反腐敗法律。

1.8“是指與美國聯邦和州證券、稅收和其他適用法律、規則和法規、公司股票上市或報價的任何股票交易所或報價系統的適用規則以及授予獎項的任何外國國家或其他授予獎項的管轄區的適用法律和規則有關的股權獎項計劃的管理的要求。「」指的是任何國家、超國家、區域型、州、地方法律、條約、法規、規章、行政法規、指導意見、條例、判決書、法令、指令、禁令、命令、法院、仲裁員、監管機構或管理局對相關項目具有管轄權的或與主題相關的任何和所有法律、條約、法規、行政法規、指導意見、條例、判決、法令、指令、禁令、許可證，包括反腐敗法和出口管制法。

1.9“收購提案「」在第2.8節中有所述。

1.10“仲裁「」代表【】***].

1.11“作業與承擔協議(assignment and assumption agreement)「」在第2.2(b)(i)節中設定的含義。

1.12“承擔的負債「」在第2.3節中所指的意思。

1.13“（b）在交割時，買方應向賣方交付以下文件：購買價格的75％（其中25％將由買方律師保留並支付給賣方，作爲買方確認購買資產正常工作的證明）；以及買方秘書或助理秘書（或相當於該等官員）出具的證書，證明以下內容：（i）買方的官員的名稱和簽名，其被授權簽署本協議、交易文件和將在此類文件下交付的其他文件，（ii）附有買方董事會採用的所有決議真實和完整的副本，這些決議授權其執行、交付並執行本協議類交易文件和計劃通過此類文件的交易，並且（iii）所有這些決議都是有效的並且是在有關此類交易的情況下制定的決議。並執行。買方應當在交割後10個工作日內向賣方和託管代理交付完全簽署的實質股份證書。「」在第2.2(b)(ii)節中所指的含義。

1.14“藍松鴉” 表示Bluejay Therapeutics, Inc.，一個特拉華州的公司。

1.15“藍鳥許可證「」指的是2024年1月28日，exicure和藍鳥之間簽訂的某項專利許可協議。

1.16“日曆季度”意味着每個日曆年的1月1日、4月1日、7月1日或10月1日開始的每個三(3)個月期間；但是，第一份協議期間的第一個日曆季度將從結束日起延續至結束日所在的日曆季度末；而本協議期限的最後一個日曆季度將在本協議到期或終止時結束。

1.17“日曆年「日曆年」指的是從1月1日開始到同一年的12月31日結束的時期；但須注意的是，（a）本協議項下的第一個日曆年將由簽約日期開始，至同一年的12月31日結束；（b）本協議項下的最後一個日曆年將由本協議終止或到期當年的1月1日開始，至本協議終止或到期結束。

1.18“開空「」在第8.1節中的含義。

1.19“結盤「」在第2.2(a)節中有所指。

1.20“結束日期。「」在第2.2(a)節中有所述。

1.21“Compound「化合物」指由Exicure構思、發現或取得的任何化合物（包括小分子和生物製品），或者是任何研究和開發活動的對象（包括與項目有關的活動），無論是（i）2023年1月1日之前的任何時間還是（ii）2023年1月1日後的項目中，包括某種名爲Cavrotolimod的TLR9激動劑化合物，其結構描述在附表1.21中。

1.22“保密信息「資產」指任何專有或非公開信息，包括與被收購資產、Flashpoint、exicure、任何一方關聯公司或其業務、資產、財產、產品或項目相關的書面、電子、口頭或視覺信息，包括所有備忘錄、分析、彙編、收集、預測或其他文件或材料，只要這些文件或材料包含或基於前述信息。爲避免疑問，從收盤之後，所有在被收購資產內或與之相關的專有技術和其他信息（包括任何收購合同的條款和條件），應被視爲Flashpoint的機密信息，不受第6.1(a)條所列例外條款的約束，exicure應對此負有第6條規定的義務。

1.23“(1)(2)「」在第4.1節中所定義。

1.24“擬議的交易”指本協議及任何相關文件所 contemplat 的交易。

1.25“合同「」指任何具有法律約束力的合同、協議、義務、承諾、安排、理解、文書、許可、特許經營權或許可證，無論是口頭還是書面。

1.26“控制「」或「」控制的土地/地塊”在任何化合物或知識產權方面表示，一個人具有合法授權或權利（無論是通過所有權，許可證還是其他方式）授予他人訪問、許可或轉讓權利，或者以其他方式披露此類化合物或知識產權下的專有或商業祕密信息，而無須違反與第三方或任何適用法律的任何協議條款。

1.27“封面「」指（a）產品或活動及（b）專利，意指在沒有相應授權或所有權的情況下，製造/製作、使用、行銷、賣出、提供賣出、進口、出口、分銷、租賃、最終使用授權或租賃該等產品或活動，應該會對該專利構成侵權，或誘導或促成對該專利的侵權。」涵蓋」與「Controlled」有相關的含義。涵蓋「」應具有相應的含義。

1.28“分銷商”代表由Flashpoint、其聯屬公司或其被許可人委任的任何第三方來分銷、推廣和販售一款帶有特許產品軸承的產品，不論是否包裝。

在一個或多個國家，存在這樣的情況，即第三方從Flashpoint、其聯屬公司或其被許可者購買其所需的含許可費產品，並取得該含許可費產品的所有權，但在轉售該含許可費產品時不需向Flashpoint、其聯屬公司或其被許可者支付任何版稅、利潤、營業收入分享或其他類似款項。

1.29“美元「"」代表美元，而「$"」應相應解釋。

1.30“「監管當局」指任何國家或超國家政府機構，包括美國食品藥品監督管理局（及其任何繼任實體）（以下簡稱「FDA」）在美國、歐洲藥品管理局（及其任何繼任實體）（以下簡稱「EMA」）或歐洲委員會（及其任何繼任實體，如適用）在歐盟、或日本內閣府健康福祉廳，或日本藥品醫療機器等級機構（或任何繼任者）（以下簡稱「MHLW」），在日本，英國藥物和保健品監管局（以下簡稱「MHRA」），或任何國家的任何衛生監管當局均為本文所述國家藥品的開發、商業化，以及進行監管審批負責的對應機構，包括但不限於HGRAC。「歐洲藥物管理局」或任何其後繼者在擁有基本相同功能的歐盟內部機構。

1.31“扣除上述質權「負擔」指任何抵押、質押、留置權、負擔、抵押附記、安全權、通行權、侵佔、限制（包括使用限制）、選擇權、信託契約、保留標題、有條件銷售或其他安全安排，或任何許可，訂單或收費，或任何所有權或使用的不良主張，或限制任何第三方轉讓的任何類型協議，或任何其他第三方或限制權利任何附加負擔。

1.32“排除資產“”指的是第2.1條中所述的含義。

1.33“受排除合同排除在外”表示附表1.33列明的合同

1.34“執行官”在第9.1條中有所定義。

1.35“exicure文件“文件”指的是由Exicure或其聯屬機構代表或準備的所有報告、文件、檔案和書面材料（包括專利檔案，但不包括監管申報和監管文件），這些文件是為了研究、開發或製造任何化合物或產品或進行任何計劃而製定或準備的。

1.36“exicure IND信件”在第2.2(b)(iii)條款中所述。

1.37“exicure已註冊IP”在第7.2（f）（i）條款中所述的含義。

1.38“exicure受益人具有第8.1條所規定的含義

1.39“利用「」相當於及包括所有相關含義，如下所述：研究開發、商業化、設計、測試、修改、生產、委託生產、維修、委託維修、使用、曾使用、賣出、曾賣出、供售、曾供售、進口、曾進口、出口、曾出口、複製、推廣、行銷和分銷，包括商業活動，用於產品上市準備。

1.40“出口管制法律「應指」：（a）所有適用的美國出口管制法律，包括《武器出口管制法》（22美國法典39章）、《國際緊急經濟措施法》（50美國法典§§ 1701等）、《與敵國交易法》（50美國法典附錄§§ 1等）、《1979年出口管理法》（50美國法典附錄§§ 2401等）、《1986年美國國內稅收法》第999部國際抵制條款，以及所有與前述相關的一切規則、法規和行政命令，包括但不限於這些。

受限於《國際武器貿易條例》（22 C.F.R. §§ 120等）、《出口管理條例》（15 C.F.R. §§ 730等）、以及由美國財政部外國資產控制辦公室實施的規定；以及（b）由任何國家、組織或其附屬機構所實施對任何物品的出口管制，而無論其轄區內的任一方或其聯屬機構開展或從事業務的國家或地區。

1.41“「監管當局」指任何國家或超國家政府機構，包括美國食品藥品監督管理局（及其任何繼任實體）（以下簡稱「FDA」）在美國、歐洲藥品管理局（及其任何繼任實體）（以下簡稱「EMA」）或歐洲委員會（及其任何繼任實體，如適用）在歐盟、或日本內閣府健康福祉廳，或日本藥品醫療機器等級機構（或任何繼任者）（以下簡稱「MHLW」），在日本，英國藥物和保健品監管局（以下簡稱「MHRA」），或任何國家的任何衛生監管當局均為本文所述國家藥品的開發、商業化，以及進行監管審批負責的對應機構，包括但不限於HGRAC。「”」代表美國食品藥物管理局或其任何後繼實體。

1.42“「首次商業銷售」指的是在每個國家上，獲得所有銷售許可證明之後，產品首次供一般大眾使用或消費的銷售；但以下情況不構成「首次商業銷售」：(a) 向子公司或者特許經營者售出；(b) 將產品用於臨床試驗以外的開發活動；(c) 將產品提供給真正的慈善目的、同情用途或樣品。「首次銷售」指對任何產品，在該國的監管機構核准後，向該國的第三方進行的第一次銷售，如果需要該監管機構的核准；或者如果不需要該核准，則指首次進行的銷售。

1.43“閃點IND信函”在第2.6條所規定的意思。

1.44“Flashpoint被保障方”在第8.2條所載有特定含義。

1.45“政府當局「政府機構」指任一美國聯邦、州或地方機構或當局，或任何外國政府或其政治次分支，或任何跨國組織或當局，或有權行使任何行政、執行、司法、立法、警察、監管或稅收權力或權限的機構、機關或委員會，或任何法院或法庭（或其部門、局或分支），或任何政府仲裁員或仲裁機構。為明確起見，任何監管當局均為政府當局。

1.46“政府官員「政府當局」指(a) 任何政府機構的官員或員工，(b) 代表政府機構擔任正式職務的任何人，(c) 任何由政府機構持有大多數或完全擁有的人的官員或員工，(d) 任何國際公共組織的官員或員工，例如世界銀行或聯合國，(e) 任何政黨的官員或員工或代表政黨擔任官方職務的任何人，或者(f) 任何政治職位候選人。

1.47“「IND」指根據美國21C.F.R.第312部分提交給FDA的調查性新藥申請（包括任何修正或補充），包括任何相關修改。本文中對IND的引用應包括，如適用，任何在美國以外的調查產品在任何其他國家或國家組織（例如歐盟臨床試驗申請）的可比申報。「申請」代表向FDA提交的一項新藥申請，或是在美國以外的國家向監管機構提交的類似申請，用於啟動一項藥物產品的臨床試驗。

1.48“受益人「” 意指 exicure 賠償人或 flashpoint 賠償人。」

1.49“知識產權「」代表所有權利、標題和利益，包括但不限於，全球範圍內所有類型和性質的智慧財產權、無形行業財產權和專有權利，包括但不限於(甲)專利、技術秘密、版權、商標、軟體、域名、社交媒體帳號和處理帳名，(乙)任何類似、相應或等效於前述任一項的權利，(丙)所有其他專有權利和智慧財產權，包括但不限於與科技相關的權利，(丁)任何及一切登記、申請、記錄、執照、普通-

與前述任何法律權利、法定權利、行政權利和合同權利相關的所有權利，包括起訴和追討過去、現在和未來損害賠償金的權利，以及（e）所有副本和前述任何內容的有形體現，如適用的話（以任何形式或媒體）。

1.50“發明者信函”在第7.2(w)條款中的含義已載明。

1.51“發明者” 意味着Aleksandar Filip Radovic，Richard Kang，Subbarao Nallagatla，Christopher C. Mader和Sergei Gryaznov。

1.52“庫存” 指exicure或其關聯公司存儲的卡沃託利莫得現有庫存，包括卡沃託利莫得藥物物質、藥品以及穩定性研究樣本。

1.53“「知識產權合同」是指所有包含知識產權授權、所有權或利益授予的合同，根據這些合同，(a) 公司從任何第三方獲得或授予任何許可、不起訴承諾、共存協議、和解協議或其他權利、所有權或利益，或(b) 公司明確受到限制，不能使用此定義中任何對公司業務至關重要的知識產權，截至本協議簽署之日，但不包括任何(i) 在常規業務過程中籤訂的保密合同，(ii) 提供的「即插即用」服務的合同，以及(iii) 附帶於向客戶出售產品或購買或使用設備、試劑或其他材料的銷售必要合同。「」在第7.2(f)(v)節中有所規定。

1.54“IP內部許可證”在第7.2(f)(v)款中所指的含義。

1.55“IP的外部許可證「」在第7.2(f)(v)節中所述。

1.56“知識產權「」表示任何和所有相關交易機密、數據、技術信息、專業技術、流程、程序、組成部分、裝置、方法、測定、配方、協議、技術、設計、規範、軟件、算法、營銷報告、測試數據（包括藥理學的、毒理學的、臨床的信息和測試數據）、分析和質量控制數據（包括藥物穩定性數據）以及製造技術和數據（包括配方數據）。

1.57“負債「」指任何直接或間接的債務、責任、評估、費用、索賠、損失、損害、不足、義務或責任，已知或未知，有爭議或無爭議，聯合或分別，既得或未獲得，履行的或未履行的，固定或未固定，成熟或不成熟，清償或未清償，有擔保或無擔保，可確定或不可確定，已發生或未發生，絕對或非絕對，實際或潛在，偶然性或其他（包括任何擔保、信用證、履約信用或有關保險損失準備金的任何責任）。

1.58“受許可方「」表示任何第三方，該第三方具有Flashpoint授權或從其他持有者獲得Acquired IP下商業化有Royalty-Bearing Product的許可，但不包括分銷商。

1.59“許可費底限”在第4.3節中定義。

1.60“損失「」在第8.1節中的含義。

1.61“淨銷售額「」表示Flashpoint、其關聯公司或許可方（以下簡稱「銷售方」）從非許可方的第三方出售或其他商業轉讓帶版稅產品所收到的總金額，減去以下根據適用會計準則和銷售方嚴格執行的標準內部政策和流程按實際情況計算的金額。售方來自非許可方的第三方爲銷售或其它商業處置帶版稅產品而支付的金額，減去根據適用會計準則和銷售方一貫執行的標準內部政策和程序按實際情況計算的以下扣除項

有關此類銷售的交易、數量、現金折扣、津貼、信貸或分配，以及一貫適用的內容如下：(a) 任何形式的貿易、數量和現金折扣、津貼和信貸，但明確排除與非專利-軸承產品無關的折扣或津貼；(b) 降價、退單及任何其他減少所開票據或發票的總額的津貼；(c) 產品退回或退貨，包括召回或破損貨物和賬單錯誤、信貸和折讓以及壞賬；(d) 因Royalty- Bearing產品而應計及實際支付或記入任何政府機構（或其代理人或機構分支）或任何第三方支付方、管理人員或承包商，包括但不限於受管理的醫療保健組織、藥店福利管理者（或其等價物）或其代理人、購買者、償付人或交易客戶，以及與專利-軸承產品相關的任何強制性付款，並由於醫療保健改革政策而產生的政府徵收費用；(e) 法律要求的折扣（或其等價物）、包括要求的退單和追溯性價格調整；(f) 運輸、貨運、郵資費用和其他費用，如保險費，相應與之有關，每項費用均列爲賬單或發票上針對第三方的特定款項；(g) 分配給適用專利-軸承產品銷售的根據《患者保護與平價醫療法案》，Pub.L.No. 111-148（經修訂）向處方藥品製造商徵收的年費部分；(h) 涉及商品生產、銷售、運輸、交付或使用而徵收或衡量的稅費、關稅、消費稅、進口稅和/或其他政府收費，每項費用均列爲賬單或發票上針對第三方的特定款項；以及(i) 與適用會計準則一致且不與前述條款（a）-（h）中任何扣除重複的任何其他類似和習慣性扣除。

關於任何人形機器人-軸承產品，只應支付一次版稅。銷售或其他商業處置中的人形機器人-軸承產品在銷售方之間不視爲對第三方的銷售，並在其後重新銷售給第三方最終用戶的情況下，應在淨銷售計算中排除對任何目的的計算。分銷商重新銷售人形機器人-軸承產品的情形，只要向該分銷商的銷售包含在淨銷售中，應對所有目的排除在淨銷售計算內。向第三方免費提供或以不超過銷售方針對此類人形機器人-軸承產品的完全負擔製造成本的金額提供人形機器人-軸承產品，在研究和開發（包括治療藥品IND銷售或早期獲取計劃）、臨床試驗、患者安慰使用或指定患者銷售、人道主義和慈善捐贈、貧困者計劃或用作樣品的情況下，應排除在淨銷售計算中，並且不應支付任何關於此類銷售或其他商業處置的款項。

如果銷售一個包含一個或多個活性成分的授權人形機器人-軸承產品的組合產品，如果單獨銷售仍然屬於授權人形機器人-軸承產品（“節目元件”)和一個或多個不是節目元件的活性成分（“其他元件”）（無論是組合成一個配方還是分開配方但在一個批准的單一標籤下包裝），這種組合產品以單一價格銷售（這種組合產品，一個“聯合產品），根據本協議確定應付的版稅的銷售淨額應按國家的實際銷售淨額計算，

(根據上述條件確定)由分數A/(A+B)計算，其中A是包含該節目組成部分但不包含其他組成部分的產品在適用國家的平均毛售價，b是包含其他組成部分但不包含該節目組成部分的產品在適用國家的平均毛售價。如果A可以確定但b無法確定，則該特許權產品的淨銷售額將通過將該組合產品的淨銷售額乘以分數A/C計算，其中A是包含該節目組成部分但不包含其他組成部分的產品在適用國家的平均毛售價，C是該組合產品的平均毛售價。如果b可以確定但A無法確定，則根據將該組合產品的淨銷售額乘以除以(B/C的1)的分數計算該特許權產品的淨銷售額，其中b是包含其他組成部分但不包含該節目組成部分的產品在適用國家的平均毛售價，C是該組合產品的平均毛售價。如果無法計算A和b，因爲適用產品沒有在特定國家銷售，則淨銷售額的調整將由各方誠實地並相互同意地確定，以合理反映該節目組成部分對該組合產品的總公平市場價值的貢獻。如果各方無法就此公平市場價值達成一致意見，該爭端應根據第9條解決。

1.62“西北「」在第2.3節中所指的意思。

1.63“西北負債「」在第2.3節中所指的意思。

1.64“專利轉讓協議”在第2.2(b)(iv)條款中所指的含義。

1.65“專利「專利」指所有板塊，包括任何國家或超國家管轄範圍內的專利和專利申請，包括任何優先權、替代品、分案、續展、部分續展、再發行、續訂、註冊、確認、再審、延伸，任何前或後授予形式的任何前述任何所述，任何確認專利或註冊專利或附加專利，實用新型，專利期限延長或恢復，以及補充保護證書或繼續審查請求等，包括任何前述可能存在的任何外國相應專利。

1.66“持有「個體指任何個人、合夥企業、有限責任公司、公司、協會、信託、非法人組織、政府機構或權力機構或其他實體。」

1.67“在履行日期之前的CDA「」代表着Exicure與Flashpoint於2024年6月18日簽署的相互保密協議，隨後於2024年6月20日進行了修訂。

1.68“產品「藥品」指任何含有任何化合物（單獨或與其他活性成分一起）的藥品，在所有形式、表現形式、配方、給藥方法和劑型中；以及在不包括在子句（a）中的範圍內，任何人形機器人-軸承產品，一種開發、構思、發明或化簡的產品，各自指（a）和（b）

在2023年1月1日之前練習或在2023年1月1日後與某一節目相關聯。

1.69“計劃「具有Exicure擁有或控制的生物技術領域內的任何研發計劃，截至2023年1月1日，如附表1.69所載，包括其TLR9激動劑計劃，以及在交割日期之前對任何此類研發計劃進行的任何工作。」

1.70“程序知識產權「」指的是所有專利、專有技術、商標以及Exicure或其關聯公司在截止日期時擁有或被許可的其他知識產權，這些知識產權(a) 是由Exicure或其關聯公司生成或使用，或者代表它們生成或使用，用於與任何化合物、產品的研究、開發或生產或任何項目的進行有關；(b) 對於任何化合物或產品的研究、開發、生產或商業化，或任何項目的進行是必要的或合理有用。

1.71“項目專利板塊「」意味着項目知識產權中的所有專利。

1.72“購買價格分配「」應按照第2.5節的規定解釋。

1.73“監管批准「」表示在該領土市場上銷售產品所需的所有相關監管機構批准（包括所有適用的定價和報銷批准）。

1.74“監管機構”指在領土範圍內批准臨床試驗或製造、營銷、銷售、報銷或定價產品的任何政府監管機構，包括FDA和EMA。

1.75“監管文件”表示所有(一)包括監管文件的所有文檔，包括所有提交的報告和函件，與之相關的函件和報告，涉及商業分銷、銷售或營銷任何產品的，向任何監管機構提交或收到的，以及相關支持文件，包括所有監管藥物清單、廣告和推廣文件、年度和定期報告、不良事件文件和投訴文件，以及(二)任何人與任何監管機構進行交流的會議記錄和官方聯繫報告(包括與任何監管機構交流的通信和相關支持文件)和(三)包含在前述任何文件中的數據(包括臨床和臨床前數據以及CMC數據)。

1.76“監管文件“所有申請和提交、審批和辦公室、註冊和授權（或者免理）和選擇員的擴展、生產或商品化的價值用來或者從任一國家或簡區的任一監管機構獲得或者取得所有和消費者。

1.77“相關文件「」在第2.2(b)(vi)節中所指的意思。

1.78“代表「人」表示對於任何個人而言，包括但不限於所有董事、管理人員、僱員、顧問、財務顧問、律師、會計師和該個人的其他代理人。

1.79“保留的負債”在2.4節中有所指。

1.80“具有人形機器人-軸承的產品” 表示任何產品（無論是目前已知的還是今後開發的），該產品由計劃專利的有效聲明覆蓋，在銷售該產品的國家或者以其他方式使用，含有或由任何化合物組成。

1.81“Royalty Floor”在第4.2節中所載明。

1.82“專利權期限「」指的是，按照按國家和具有Royalty-人形機器人-軸承產品區分的方式，從在該國家的Royalty-人形機器人-軸承產品的首次商業銷售開始，並在以下情況中最晚一種的結束期間：(a) 該國家涵蓋該Royalty-人形機器人-軸承產品的項目專利的最後到期有效索賠到期，以及(b) 該國家對該Royalty-人形機器人-軸承產品的首次商業銷售週年紀念日。

1.83“Rules「」在第9.2(a)節中定義。

1.84“SEC「」代表美國證券交易委員會。

1.85“指定合同「某項協作、選擇和許可協議」是由Exicure公司和艾普生生物製藥有限公司於2021年7月30日簽訂的。某項 Exicure公司和艾普生生物製藥有限公司於2022年12月12日簽訂的協作、選擇和許可協議的相互終止協議某項 Exicure公司和艾爾建制藥國際有限公司於2019年11月13日簽訂的協作、選擇和許可協議某項與艾爾建制藥國際有限公司於2022年12月5日簽署的信函協議特定的 Exicure與Dermelix Biotherapeutics之間的許可和發展協議日期爲2019年2月17日特定的 Exicure與Purdue Pharma L.P.之間的研究合作、選擇和許可協議日期爲2016年12月2日。

1.86“稅務「稅」指任何形式的稅款（包括任何所得稅、特許稅、資本利得稅、預付稅、營業稅、增值稅、附加稅、消費稅、從價稅、轉讓稅、印花稅、銷售稅、使用稅、財產稅、營業稅、職業稅、庫存稅、佔有稅、代扣稅或工資稅）、徵收、評估、關稅、徵收、費用（包括任何罰款、處罰或利息）、以及任何相關費用或金額，即已經或將來可能（a）由任何政府機構徵收、評估或徵收，或（b）作爲任何人的受讓人或繼任人，或因承擔此類稅款的明示或暗示義務或爲補償其他任何人的稅款而產生的上述類型金額的支付責任。

1.87“納稅申報「報告」指提交給或要求提交給任何政府機構的任何申報、報告、聲明、評估、時間表、通知、通告、表格、選舉、證書或其他文件或信息，與確定、評估、徵收或支付任何稅款或與實施、執行、遵守與稅款有關的任何適用法律有關的文件。

1.88“「指阿拉伯聯合酋長國、沙特阿拉伯、科威特、約旦、卡塔爾和阿曼，有可能擴展到阿爾及利亞、巴林、塞浦路斯、埃及、伊朗、伊拉克、以色列、利比亞、黎巴嫩、摩洛哥、巴勒斯坦領土、敘利亞、突尼斯、土耳其和也門；但許可方可以通過書面通知許可方在發生牽涉該國或地區的任何貿易禁令的情況下，將該國或地區從本條款之內排除。」「」表示全球。

1.89“第三方「」指的是exicure或flashpoint之外的個人或exicure或flashpoint的關聯公司。

1.90“閾值「」在第11.8(a)節中所指的意思。

1.91“商標「標的」指任何單詞、名稱、符號、顏色、產品形狀、指定或裝置，或任何組合，其作爲標識來源，包括任何商標、外觀設計、品牌標記、服務商標、商業名稱、品牌名稱、產品構造、標誌或業務符號，無論是否註冊。

1.92“「轉讓」還將被視爲發生在任何操作持有人(或該操作持有人的允許受讓人)有B類普通股股份的非盈利機構(或該股份的任何受益人)持有該B類普通股股份的頂層支配權或獨家投票權控制時，就該B類普通股股份而言，操作持有人(或其允許受讓方)不再保留獨立支配權(在操作持有人和其允許受讓方之間)和其對該安全的投票或投票的獨佔支配權(包括通過委託、投票協議或其他方式)，情況下(在這種情況下)。即使是這種情況，以下任何情況也不被視爲「轉讓」:「」在第2.6節中有所規定。

1.93“美國「」或「」美國.「美國」指美利堅合衆國及其領土和附屬地（包括哥倫比亞特區和波多黎各）。

1.94“有效索賠「有效權利要求」，指（a）尚未被放棄、註銷、或被有管轄權的法院或其他政府機構做出的具有不可上訴權的決定永久撤銷、不可執行或無效，並且未因重新頒發、棄權或其他方式而被認定爲無效或不可執行的已頒發且未過期的專利權要求；或者（b）尚未最終被放棄、最終被拒絕或過期，且自最早優先申請專利申請文件提交日期起至少七（7）年內仍處於待決狀態的專利申請中的專利權要求。在提交日期後七（7）年內提交的專利申請中的任何專利權要求在未被授予並符合（a）部分要求之前不會被視爲有效權利要求。

第2條

資產出售；轉讓；獨家權

2.1向 Flashpoint 出售資產。附表2.1中規定的任何資產除外（”排除的資產”），Exicure特此向Flashpoint出售、轉讓、轉讓和交付，Flashpoint特此從Exicure購買和收購，每種情況均截至截止日期，不含除承擔負債之外的所有負債，以及Exicure或其關聯公司擁有、使用或持有的全部資產、財產、特權、索賠、所有權、利益和權利與任何化合物有關或以其他方式相關的任何化合物，

產品或項目，或其所有權或使用權，無論這些資產、財產、特權、索賠或權利是真實的、個人的還是混合的，有形的或無形的，在何處都可找到，無論這些資產、財產、特權、索賠或權利是否具有會計目的的任何價值或者是否在Exicure的任何賬簿或財務報表中載列或明確提及（統稱「資產」）已收購的資產，包括以下所有內容：

(a)所有與任何複合物、產品或計劃相關的合同，包括附表2.1(a)中列出的合同以及與發明人簽訂的任何發明轉讓協議，將Exicure在發明人提供服務的過程中開發的發明和知識產權的所有權轉讓或授予Exicure，但不包括排除的合同（“獲取合同”);

(b)獲取的所有知識產權和起訴或主張針對任何或所有獲取的知識產權以及針對過去、現在或未來任何或所有侵權行爲的權利和優先權和保護這些利益的權利以及保留其中的任何和所有金額；

(c)所有交易文件和監管備案，由exicure或其關聯公司持有在收盤日期之前存在，包括，對於Cavrotolimod IND編號139964，對於ASt-005，研究方案編號ASt-005，EudraCt編號2015-004349-17，以及對於XCUR17，研究方案編號xcur17-101，EudraCt編號2016-005174-35；

(d)所有板塊 exicure 文檔;

(e)所有與任何化合物或產品相關的安全數據庫;

(f)所有板塊、產品或計劃相關的針對第三方的所有權利主張、反主張、信貸、訴因、賦選權、追索權利，以及補償權利或抵銷權利。

此外，收購的資產將包括，exicure將轉讓給Flashpoint，所有過期或終止的與方案、複合體或產品相關的合同副本。

2.2關閉；關閉交付成果物.

(a)結盤。擬議交易的結束（“結盤”）應通過交換本第2.2節所述的協議、文件、證書和其他文書的電子副本進行，時間爲舊金山時間上午9點，第二個營業日，而這之前需要滿足（或在允許的情況下放棄）第10條所述的條件（除非根據條款，這些條件應在結束時滿足或放棄，但須滿足或放棄此類條件的要求），或根據Flashpoint和exicure協商一致的其他地點、時間和日期進行。結束交易的日期被稱爲“結束日期。.”

(b)Exicure結束交付成果。在結束交割之日起，exicure應當交付或導致交付給Flashpoint：

(i)一份附件A附贈的《轉讓及承諾協議書》的形式。作業與承擔協議(assignment and assumption agreement)”);

(ii)隨附件b（“（b）在交割時，買方應向賣方交付以下文件：購買價格的75％（其中25％將由買方律師保留並支付給賣方，作爲買方確認購買資產正常工作的證明）；以及買方秘書或助理秘書（或相當於該等官員）出具的證書，證明以下內容：（i）買方的官員的名稱和簽名，其被授權簽署本協議、交易文件和將在此類文件下交付的其他文件，（ii）附有買方董事會採用的所有決議真實和完整的副本，這些決議授權其執行、交付並執行本協議類交易文件和計劃通過此類文件的交易，並且（iii）所有這些決議都是有效的並且是在有關此類交易的情況下制定的決議。並執行。買方應當在交割後10個工作日內向賣方和託管代理交付完全簽署的實質股份證書。”);

(iii)一封轉讓Cavrotolimod IND編號139964所有權的信函，表格見附件C（exicure IND 信函”);

(iv)附件E所附的專利轉讓協議（“專利轉讓協議”);

(v)請填寫完整準確的IRS W-9表格；和

(vi)其他轉讓和過戶工具等合理必要文件，以便將收購資產的良好和有市場性的所有權轉讓給Flashpoint（所有這些文件，連同轉讓和承受協議、轉讓證書和exicure IND信函，"相關文件”).

(c)Flashpoint結束交付成果在結束時，Flashpoint應交付或導致交付給exicure：

(i)Assignment and Assumption Agreement已由Flashpoint及/或其適用的關聯公司簽署並執行；

(ii)銷售清單，由Flashpoint和/或其適用的關聯公司執行。

2.3假設負債。根據此處包含的Exicure的條款、條件、陳述和保證，並以第2.4節爲前提，Flashpoint特此假設並同意在到期時立即全額支付、履行和清償：(a) 自截止日期起生效的Exicure在收購合同下的任何責任，但僅限於此類負債 (i) 在截止日期之後首次產生或與之相關的範圍，(ii) 不產生於任何負債 Exicure或其關聯公司違反任何此類收購合同的任何條款，(iii) 並非源於或與之相關在截止日期或之前發生或存在的任何事件、情況或狀況，以及 (iv) 可根據此類收購合同的條款合理確定，以及 (b) (i) 構成對西北大學或其任何附屬機構的損害賠償的任何責任 (”西北”) 與仲裁所依據的事實有關而產生 (”西北負債”）以及（ii）在截止日期之後與Flashpoint與西北航空之間的任何合同、交易或關係有關或產生的任何負債，在每種情況下（（i）和（ii））與任何收購資產（（a）和（b）共同相關的範圍內，”假設負債”）。Flashpoint應控制仲裁（須遵守第8.3（b）節規定的限制和程序），未經Flashpoint書面同意，Exicure不得對此類仲裁採取任何行動，不得無理拒絕。爲澄清起見，Exicure不得承擔任何種類、性質或描述的任何應計負債務，也不承擔任何責任，

絕對的、有條件的或其他情況下，明確理解exicure明確否認對任何已承擔債務的任何明示或暗示假設。

2.4保留的負債除了承擔的債務外，Flashpoint 不應承擔也不對 exicure 或其關聯公司的任何種類、性質或描述的債務承擔任何責任，無論是已發生、絕對、或有條件的，Flashpoint明確聲明除了已承擔的債務之外不承擔任何明示或暗示的責任（統稱“保留的負債”).

2.5購買價格分配。Flashpoint 應根據《守則》第 1060 條準備對價（以及任何其他被視爲美國聯邦所得稅對價的金額）的分配（以下簡稱”購買價格分配”）。Flashpoint應在收盤後不遲於九十（90）天內向Exicure提交收購價格分配草案。在收到此類收購價格分配草案後的三十 (30) 天內，Exicure應就此類收購價格分配草案向Flashpoint提供書面意見，Flashpoint應認真考慮Exicure提出的任何合理評論。如果Exicure未能在收到購買價格分配草案後的三十（30）天內向Flashpoint提供書面意見，則該購買價格分配草案將成爲最終的並對所有各方具有約束力。除非適用法律或政府機構另有要求，否則Flashpoint和Exicure應以與購買價格分配一致的方式提交所有納稅申報表。如果任何政府機構對購買價格分配提出異議，則收到爭議通知的一方應立即以書面形式將此類通知和爭議解決辦法通知另一方。

2.6轉移。在截止日期後的五 (5) 個工作日內，Exicure應向美國食品和藥物管理局提交Exicure IND信函，Flashpoint應向美國食品和藥物管理局提交一封信函，承認IND號139964的所有權，其形式和實質內容與本文附件D所附表格基本相似（”閃點 IND 信函”）。Exicure應向Flashpoint或其指定人員提供所有收購資產，不向Flashpoint支付任何額外費用或費用（”轉移”）根據附表2.6中規定的時間表，在收盤時沒有轉移到Flashpoint。在轉讓方面，Exicure應向Flashpoint提供收購資產中包含的任何和所有文件、電子記錄和數據庫、樣本和其他有形材料的原件的電子副本（儘可能採用微軟Word格式，否則爲可搜索的PDF格式或其他商定格式），並應Flashpoint的合理要求，向Flashpoint提供實際訪問權限。根據Flashpoint的合理要求，Exicure應在不向Flashpoint提供任何額外費用或費用的情況下，提供合理的技術支持（通過電話會議、視頻會議、電子手段或面對面，每種支持都應在正常工作時間進行，並應提前合理通知），以支持轉移。儘管如此，如果Flashpoint或Exicure後來得知任何本應但尚未作爲轉讓的一部分轉移到Flashpoint的收購資產，則該方應立即通知另一方，Exicure應立即將此類收購資產轉讓給Flashpoint或其指定人。

2.7不可轉讓資產。儘管本協議中有任何相反規定，本協議不構成協議，用於賣出、轉讓、讓與或

如果試圖出售、轉讓、分派或交付任何已獲資產會導致違反適用法律，或需要不是本協議當事方或本協議當事方的關聯方（包括任何政府機構）同意、授權、批准或放棄的人同意，授權、批准、豁免未在交割之前獲得，exicure將盡最大商業努力獲取任何必需的同意、授權、批准或豁免。一旦獲得此類同意、授權、批准或豁免，exicure應以無需額外對價的方式將涉及此類同意、授權、批准或豁免的相應已取資產出售、分派、轉讓給Flashpoint。除非獲得此類同意、授權、批准或豁免，或如果試圖出售、轉讓、分派或交付任何這樣的資產將是無效的，或將不利影響exicure或Flashpoint的權利，以致Flashpoint事實上無法接收此類已取資產的全部權利或利益，exicure和Flashpoint將合作安排，根據本協議，其中Flashpoint將以經濟和（在適用法律允許的範圍內）操作上的等價物獲得此類已取資產的轉讓，包括分包、轉讓或出租給Flashpoint，或exicure將在Flashpoint的費用下對第三方主張exicure對該第三方的所有權利，以便Flashpoint從事Flashpoint的義務，同時承擔Flashpoint的費用。一旦exicure收到與此類已取資產相關的所有款項，exicure將及時支付給Flashpoint，而Flashpoint應就根據本條款下的安排相關的範圍內的所有責任支付、辯護、清償和執行。

2.8獨家協議Exicure不得，也不得授權或允許其任何關聯公司或其或他們的代表，直接或間接地（i）鼓勵、徵求、發起、促成或繼續關於收購提案的詢問；（ii）就可能的收購提案與任何人進行討論或談判；或（iii）就收購提案簽訂任何協議或其他文件（不論是否具約束力）。Exicure應立即停止並導致終止，必須導致其關聯公司及其所有代表立即停止並導致終止，以前進行有關收購提案的任何人員所進行或可能導致的所有現有討論或談判。在本協議中，「收購提案」應指任何人（Flashpoint除外）提出的有關已收購資產的出售、租賃、交換或其他處置的詢問、建議或要約或其任何部分。Exicure應及時（並且在收到Exicure或其代表的收到之日起三個工作日內）在口頭和書面上通知Flashpoint任何收購提案、有關任何收購提案的信息請求或任何與收購提案有關或可能合理預期會導致收購提案的詢問，該收購提案、請求或詢問的實質條款和條件以及提出其的人的身份。Exicure同意，對於未遵守本第2.7節的權利和補救措施將包括通過任何有管轄權的法院具體執行該規定，承認並同意任何此類違約或恐嚇的違約將給Flashpoint造成不可挽回的損害，金錢賠償無法提供充分的補救措施。收購提案提出任何（Flashpoint除外）關於所收購資產或其任何部分的出售、租賃、交換或其他處置的任何詢問、建議或要約。Exicure應及時（並且在Exicure或其代表收到之日起的三個工作日內）向Flashpoint口頭和書面報告任何收購提案、與任何收購提案有關的信息請求或可能導致收購提案的詢問、該收購提案、請求或詢問的主要條款和條件，以及提出這些請求的個人的身份。Exicure同意，未遵守本第2.7節的權利和補救措施包括要求任何有管轄權的法院具體執行該規定，應認可並同意這樣的違約或威脅違約將給Flashpoint造成不可挽回的損害，貨幣賠償無法提供充分的補救。

2.9許可權回收Flashpoint特此授予Exicure及其關聯公司在收購資產中的所有權利下的全球性、不可撤銷、免許可費、可轉讓、可轉讓的權利和許可，包括知識產權，在買賣、銷售、分銷和處置庫存直到Closing日期Exicure或其關聯公司控制的所有庫存全部耗盡。爲避免疑義，Exicure 及其關聯公司無需向Flashpoint作出任何帳戶報告或以任何方式支付任何金額（包括任何版稅）以銷售任何庫存。本協議無妨阻止，且不應解釋爲阻止Exicure或其關聯公司以任何其認爲合適的方式出售或處置任何庫存。

第3章

開發、製造和商業化

3.1在交易雙方之間，自收盤日期起，Flashpoint應獨自控制、管理和決定節目、研究、開發（包括監管活動）、製造和商業化化合物和產品，且應獨自承擔費用。在不限制前述內容的情況下，Flashpoint應獨自負責並承擔備制並提交產品法規批准的註冊文件的全部費用，Flashpoint應成爲產品的所有法規批准持有者，Flashpoint應擁有所有相關提交，並且Flashpoint應設定所有產品的價格。

第4條

(1)(2)

4.1考慮。作爲出售、運送、交付、轉讓和轉讓所收資產的對價，Flashpoint將根據在下述每個日期當天或之前向Flashpoint提供的電匯指示，通過電匯向Exicure支付一百萬五十萬美元（合1,500,000.00美元）（減去Exicure根據第4.4節應付的任何款項）（”考慮”），其中十五萬美元（合150,000.00美元）自生效之日起已由Flashpoint支付（Exicure確認收到該款項），其餘金額應按照以下時間表支付：

(a)第一期款：在交割日後七（7）天內以現金形式支付五十五萬美元（$550,000.00）；

(b)第二筆付款：在交割日起三 (3) 個月內，以現金形式支付四十萬美元（$400,000.00）；並

(c)第三期款：在交割日期之後的第六（6）個月週年紀念日之前，支付四十萬美元現金（$400,000.00）。

4.2人形機器人-軸承的特許權使用費在適用的特許權期內，在日曆季度結束後的四十五（45）天內，Flashpoint將支付給exicure該日曆季度內Flashpoint及其關聯公司或被許可方收到的所有軸承特許產品的全球淨銷售額的版稅，如果有的話。然而，（a）如果一個軸承特許產品應支付給一個或多個其他許可方版稅義務，則Flashpoint有權從應支付給exicure的版稅中扣除對於該軸承特許產品應支付給其他許可方的版稅金額，（b）自軸承特許產品在一個國家不再受限於節目專利的有效要求的日期起，該國家銷售的該軸承特許產品的版稅率將減少50％，前提是在（a）和（b）小節的減少的累積效應不得將對exicure的有效版稅率降至淨銷售額的[***]以下（“Royalty Floor[***]的30天內將在收到的Flashpoint根據Bluejay許可協議或其子許可方銷售的軸承特許產品的所有付款（除了Flashpoint或代表Flashpoint支出的費用的返還付款）傳達給exicure，並且在Bluejay許可協議下的銷售或向exicure傳達的任何此類付款都不會導致根據本協議向exicure支付任何版稅或許可費。

4.3許可費用除了第4.2節下的運行版稅外，Flashpoint將向exicure支付許可方案專利相關項目或計劃的全部收入的[***]，包括但不限於許可發行費、期權付款、技術獲取費、合作伙伴費用或未按時支付的里程碑或預付款、週年費用，但不包括(a)運行版稅支付、(b)發行股權或真正的債務、(c)研究和開發資金（包括以低於全面負擔製造成本的價格提供材料或產品的支付），以及(d)專利費用的返還。但是，如果許可方的任何收入應支付給Flashpoint的許可方一項或多項其他許可人的許可費用義務，則Flashpoint有權從應向exicure支付的許可費用中扣除與這些被許可方收入相關的任何許可或轉讓費用，前提是支付給exicure的有效轉授權費百分比不得降低至[***]所述全部收入的百分之（上述計算）（稱爲“許可費底限”).

4.4Withholding of Taxes. Any withholding of Taxes levied by tax authorities on the payments hereunder shall be borne by Exicure and deducted by Flashpoint, from the sums otherwise payable by it hereunder, for payment to the proper tax authorities on behalf of Exicure. Flashpoint agrees to cooperate with Exicure in the event Exicure claims exemption from such withholding or seeks deductions under any double taxation or other similar treaty or agreement from time to time in force, including but not limited to providing Exicure with receipts of payment of such withheld Tax or other documents reasonably available to Flashpoint.

Article 5

Intellectual Property

5.1Patent Prosecution and Maintenance. As between the Parties, from and after the Closing Date Flashpoint shall have the sole right, but not any obligation, to prosecute and maintain all Program Patents, in its sole discretion and at its own expense and by counsel of its own choice. From and after the Closing Date, Exicure shall cooperate with Flashpoint to transfer of all prosecution and maintenance responsibilities relating to the Program Patents, which cooperation shall include: (a) transferring to Flashpoint the existing, complete patent files for the Program Patents and communicating to Flashpoint all facts and information then known to Exicure comprising or relating thereto; (b) furnishing Flashpoint with copies of all documents, electronic records, photographs, models, samples and other tangible materials in Exicure’s control that relate directly to the Program Patents, (c) executing all documents necessary to record with each applicable patent authority the assignment of the Acquired Patents to Flashpoint, including additional Patent Assignment Agreements in substantially the form attached hereto as Annex E, and (d) filing all documents necessary to transfer correspondence with the U.S. Patent and Trademark Office and other applicable patent authorities in other countries to Flashpoint and to give Flashpoint’s patent counsel power of attorney thereto.

5.2Enforcement. Exicure shall promptly notify Flashpoint of any alleged or threatened infringement or misappropriation of the Program IP, in each case of which it becomes aware. As between the Parties, Flashpoint shall have the sole right, but not the obligation, to bring a suit or otherwise take action against any Person or entity directly infringing, contributorily infringing or inducing infringement of, or misappropriating the Program IP, at its full discretion and its own expense and by counsel of its own choice, and Flashpoint shall solely retain any recovery in connection therewith. Exicure shall provide Flashpoint, at Flashpoint’s request and expense, with any assistance reasonably requested by Flashpoint with respect to the enforcement or defense of the Program Patents.

Article 6

Confidentiality, Publication and Publicity

6.1Confidentiality. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties, each Party agrees that, starting from the Closing Date until ten (10) years after the First Commercial Sale of the last Royalty-Bearing Product, it and its Affiliates shall, and shall cause their respective Representatives to, keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as provided for in this Agreement any Confidential Information of the other Party, unless the receiving Party can demonstrate by competent proof that such Confidential Information:

(a)was already known to the receiving Party or its Affiliate, other than under an obligation of confidentiality, at the time of disclosure by the other Party;

(b)was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving Party or its Affiliate;

(c)became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving Party or its Affiliate in breach of this Agreement;

(d)was disclosed to the receiving Party or its Affiliate, other than under an obligation of confidentiality to a Third Party, by a Third Party who had no obligation to the disclosing Party not to disclose such information to others; or

(e)was independently discovered or developed by the receiving Party or its Affiliate without the use of Confidential Information belonging to the disclosing Party.

6.2Authorized Disclosure.

(a)Each Party and its Affiliates may disclose Confidential Information belonging to the other Party to the extent such disclosure:

(i)is reasonably necessary to prosecute or defend litigation with respect to this Agreement;

(ii)is reasonably necessary to comply with Applicable Laws, governmental regulations or court orders; or

(iii)is to each Party or its Affiliates’ Representatives, in each case who have a need to know to perform any obligation or exercise any right of such Party under this Agreement and who agree to be bound by terms of confidentiality which are no less restrictive than those set forth in this Agreement.

(b)Notwithstanding the foregoing, in the event the receiving Party is required to make a disclosure of disclosing Party’s Confidential Information pursuant to Section 6.2(a)(ii), it will, except where impracticable, (i) give reasonable advance notice to the disclosing Party of such disclosure, (ii) use efforts to secure confidential treatment of such information at least as diligent as the receiving Party would use to protect its own Confidential Information, but in no event less than reasonable efforts, and (iii) cooperate with any efforts by the disclosing Party, at the disclosing Party’s request and expense, to secure confidential treatment of such Confidential Information. Disclosure by the receiving Party of Confidential Information in accordance with any of the foregoing provisions of this Section 6.2(b) shall not, in and of itself, cause the information so disclosed to cease to be treated as Confidential Information under this Agreement, except to the extent that, by virtue of disclosure by the receiving Party in full compliance with this Section 6.2(b), such information becomes generally known or available.

6.3Publication. Exicure and its Affiliates shall not publish or otherwise publicly disclose any data or results regarding any Program, Compound or Product without the prior written consent of Flashpoint. Flashpoint shall have the right to publish or otherwise publicly

disclose any data or results regarding any Program, Compound or Product in its sole discretion without the prior written consent of Exicure.

6.4Publicity. Neither Exicure nor Flashpoint shall, without the prior consent of the other, except as required by Applicable Laws (including those applicable to the public sale of securities), issue any press release or make any other public announcement concerning the terms of the Agreement, nor (except as set forth below) use the name of the other Party or its Affiliates. Notwithstanding the foregoing, each Party may disclose the terms of this Agreement in securities filings with the SEC to the extent required by Applicable Laws after complying with the procedure set forth in this Section 6.4. In such event, the Party seeking such disclosure shall prepare a draft confidential treatment request and proposed redacted version of this Agreement to request confidential treatment for this Agreement, and the other Party agrees to promptly (and in any event, no less than five (5) days after receipt of such confidential treatment request and proposed redactions) give its input in a reasonable manner in order to allow the Party seeking disclosure to file its request within the time lines proscribed by Applicable Laws. The Party seeking such disclosure shall exercise commercially reasonable efforts to obtain confidential treatment of the Agreement from the SEC (or equivalent foreign agency) as represented by the redacted version reviewed by the other Party. For clarity, Flashpoint shall not have any obligation to Exicure with respect to press releases or other public disclosures regarding the development, Regulatory Approval, commercialization or Exploitation of any Compound or Product or the conduct of any Program. For avoidance of doubt, Flashpoint shall be entitled to make announcements of any nature stating that it has acquired the Acquired Assets, including identification of such assets.

Article 7

Representations, Warranties and Covenants

7.1Representations and Warranties of Flashpoint. Flashpoint hereby represents and warrants to Exicure that, as of the Closing Date:

(a)Corporate Existence and Power. Flashpoint is a corporation duly organized, validly existing and in good standing under the laws of the jurisdiction in which it is incorporated and has full power and authority and the legal right to own and operate its property and assets and to carry on its business as it is now being conducted and as contemplated by this Agreement.

(b)Authority and Binding Agreement. (i) Flashpoint has the power and authority and the legal right to enter into this Agreement and perform its obligations hereunder; (ii) Flashpoint has taken all necessary authorized action on its part required to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder; and (iii) this Agreement has been duly executed and delivered on behalf of Flashpoint and constitutes a legal, valid and binding obligation that is enforceable against it in accordance with its terms.

(c)No Conflict. Flashpoint’s performance and execution of this Agreement does not and will not result in a breach of any other Contract to which it is a party.

(d)Consideration. Flashpoint has taken all necessary actions to ensure that the total amount of Consideration is currently, and will at all times between the date hereof and payment of the Third Installment, be available in cash or other form of immediately available funds by wire transfer.

7.2Representations and Warranties of Exicure. Except with respect to the Specified Contracts, Exicure hereby represents and warrants as of the Closing Date and covenants, as applicable, as follows:

(a)Corporate Existence and Power. Exicure is a corporation duly organized, validly existing and in good standing under the laws of the jurisdiction in which it is incorporated and has full power and authority and the legal right to own and operate its property and assets and to carry on its business as it is now being conducted and as contemplated by this Agreement. Exicure is duly qualified or licensed to do business and is in good standing in each jurisdiction in which ownership of the Acquired Assets makes such qualification or licensing necessary.

(b)Authority and Binding Agreement. Exicure has the power and authority and the legal right to enter into this Agreement and the Related Documents, to perform its obligations hereunder and thereunder and to consummate the Contemplated Transactions; has taken all necessary authorized action on its part required to authorize the execution and delivery of this Agreement and the Related Documents, the performance of its obligations hereunder and the consummation of the Contemplated Transactions. No other corporate proceedings on part of Exicure are necessary to authorize this Agreement or the Related Documents or to consummate the Contemplated Transactions; and this Agreement has been duly executed and delivered on behalf of Exicure and constitutes a legal, valid and binding obligation that is enforceable against Exicure in accordance with its terms.

(c)Acquired Assets. Exicure is the sole owner of the entire right, title and interest in and to all Acquired Assets (excluding the Patents disclosed in Schedule 7.2(f)(vii), which are co-owned by Exicure and Northwestern), in each case free of all Encumbrances, and has the full and legal rights and authority to sell, assign, transfer and deliver the Acquired Assets to Flashpoint. Other than the claims that are the subject of the Arbitration, there are no adverse claims of ownership to the Acquired Assets, and Exicure has not received any oral or written notice that any Person has asserted a claim of ownership or right of possession or use in or to any of the Acquired Assets, nor, to Exicure’s knowledge, are there any facts, circumstances or conditions on which such a claim could be brought in the future. At the Closing, subject to the Arbitration, Flashpoint will acquire from Exicure sole and exclusive, good and marketable title to all of the Acquired Assets, free and clear of all Encumbrances.

(d)Contracts. Schedule 7.2(d) contains a true and accurate list of all Contracts pursuant to which Exicure or any of its Affiliates enjoys any right or benefit or undertakes any obligation related to any Acquired Asset or any Program, Compound or Product, other than (i) non-disclosure agreements, (ii) licenses granted to Exicure for off-the-shelf software, (iii) invention assignment agreements with employees and consultants that assign or grant to Exicure ownership of inventions and intellectual property developed in the course of

providing services to Exicure by such employees and consultants, and Excluded Contracts. Exicure has made available to Flashpoint a complete and accurate copy of each such Contract, including all Acquired Contracts. Each Acquired Contract is in full force and effect and has not been terminated, except as disclosed in Schedule 7.2(d). No Acquired Contract has been breached by Exicure or any of its Affiliates, or to Exicure’s and its Affiliates’ knowledge, by the other party to such Acquired Contract. Exicure and its Affiliates have not received or provided any notice of breach or termination regarding any Acquired Contract. Neither Exicure nor any of its Affiliates has waived any right under any Acquired Contract. As of the Closing Date, there are no discussions or negotiations regarding any amendment or modification to or any termination of any Acquired Contract, except as disclosed in Schedule 7.2(d).

(e)Other Contracts. Other than the Acquired Contracts, there are no Contracts (i) pursuant to which Exicure or its Affiliates has obtained, or has a right to obtain, a license under or rights to use any Patent, Know-How, Trademark or other Intellectual Property Right that is relevant to any Program, Compound or Product; or (ii) to Exicure’s knowledge, pursuant to which Exicure or its Affiliates otherwise owes, or would otherwise owe, payments to a Third Party as a result of the practice of any Program IP, the conduct of any Program or the Exploitation of any Compound or Product.

(f)Intellectual Property.

(i)Schedule 7.2(f)(i) sets forth, as of the date hereof, a complete and accurate list of all registered Patents and Trademarks in the Acquired IP, including the registration number, filing date, expiration date, country or territory, registrant and owner of record in respect of each such item of Acquired IP (such items, collectively, “Exicure Registered IP”). As of the Effective Date, to Exicure’s knowledge, all Exicure Registered IP is subsisting and not invalid or unenforceable, and has been duly registered or filed with or issued by each appropriate Governmental Authority in the jurisdiction indicated in Schedule 7.2(f)(i). All necessary filing, examination, registration, maintenance and renewal fees currently due in connection with such Exicure Registered IP have been made, and all necessary documents, proofs of working or use, recordations, affidavits, and certificates in connection with such Exicure Registered IP have been timely filed with the relevant authorities in the United States or applicable non-U.S. jurisdictions, as the case may be, for the purposes of prosecuting, registering or maintaining such Exicure Registered IP up to the Effective Date. Exicure is the registered owner of each item of Exicure Registered IP which it owns or purports to own. The Exicure Registered IP has not expired or been declared invalid, in whole or in part, by any Governmental Authority, and is not subject to any interference, opposition, reissue, reexamination, cancellation or other similar proceeding which challenge the validity or ownership of such Exicure Registered IP. Each of the Program Patents listed in Schedule 7.2(f)(i) properly identifies each and every inventor of the claims thereof as determined in accordance with the laws of the jurisdiction in which such Acquired Patent is issued (or, with respect to patent applications, such patent application is pending). Each inventor named on the Patents listed in Schedule 7.2(f)(i) has executed an agreement assigning his, her or its entire right, title and interest in and to such Acquired Patent, and the inventions embodied and claimed therein, to Exicure. To Exicure’s knowledge, no such inventor has any contractual or other obligation that would preclude any

such assignment or otherwise conflict with the obligations of such inventor to Exicure under such agreement with Exicure.

(ii)Exicure exclusively owns all rights, title and interests in and to all Acquired IP (excluding the Patents disclosed in Schedule 7.2(f)(vii), which are co-owned by Exicure and Northwestern), and has the right to transfer to Flashpoint or its Affiliates under the terms of this Agreement, all Acquired IP, free and clear of all Encumbrances. Immediately following the Closing, Flashpoint shall have substantially the same rights, interest, and title in and to each item of Acquired IP as held by Exicure immediately prior to the Closing, in each case, without the payment of any additional amounts or consideration.

(iii)To Exicure’s knowledge, the Exploitation of the Acquired IP does not, and would not reasonably be expected, following commercialization, to infringe or misappropriate the Intellectual Property Rights of any other Person in existence on the Closing Date. To Exicure’s knowledge, (i) no Person or Persons has, directly or indirectly, infringed, diluted, misappropriated or otherwise violated or is or are infringing, diluting, misappropriating or otherwise violating the Acquired IP and (ii) Exicure has not brought or threatened to bring any claim, suit or proceeding against any Person alleging any such misappropriation, infringement, dilution or violation, and (iii) neither of the foregoing clauses (i) or (ii) have been asserted in any cease and desist letter or other written notice, including in the nature of offering a license or covenant not to sue, in each case relating to Acquired IP.

(iv)Except as set forth on Schedule 7.2(f)(iv), no claims have been asserted or threatened in writing by any Person against Exicure or its Affiliates, nor does there exist, to Exicure’s knowledge, any valid basis for such a claim, with respect to: (i) challenging the ownership, licensing or use of any Acquired IP; (ii) any actual or potential infringement, dilution, misappropriation or unauthorized use of Acquired IP; (iii) any actual or potential infringement, dilution, misappropriation or unauthorized use of any Third Party’s Intellectual Property Rights with respect to any Acquired IP; (iv) the validity or enforceability of any Acquired IP; or (v) asserting that the operation of any Program has infringed, diluted, misappropriated or otherwise violated any intellectual property right of any Person. Exicure has the right to bring Actions for infringement, including all rights to recover damages for past infringement, of all Acquired IP.

(v)Schedule 7.2(f)(v) sets forth a complete and accurate list as of the date hereof of all (i) Contracts in which options, rights or licenses to any Program IP are granted to Exicure by any other Person (other than (A) “commercial off-the-shelf” software, (B) non-exclusive rights or licenses granted by any Person in the ordinary course of business consistent with standard industry practices, or (C) Excluded Contracts) (collectively, “IP In-Licenses”), and (ii) Contracts in which options, rights, or licenses relating to any Acquired IP are granted by Exicure to any other Person (other than non-exclusive rights or licenses granted by Exicure in the ordinary course of business consistent with past practice or any Excluded Contracts) (collectively, “IP Out-Licenses”, and together with the IP In-Licenses the “IP Contracts”). To Exicure’s knowledge, (x) all obligations for payment of undisputed monies currently due as of the date hereof and payable by Exicure in connection with such IP Contracts have been satisfied

and (y) Exicure has not materially breached any of Exicure’s performance obligations in connection with such IP Contracts.

(vi)Exicure has used commercially reasonable efforts to protect its ownership of and rights in the Acquired IP and to maintain its trade secrets constituting Acquired IP in confidence. Exicure and its Affiliates have not made any of their trade secrets constituting Acquired IP or other confidential or proprietary information related to any Program available to any other Person except pursuant to written agreements requiring such Person to maintain the confidentiality of such information.

(vii)Except as set forth on Schedule 7.2(f)(vii), no college, university or other educational or research institution or agency, or any government, has any claim of commercial right or license to, or ownership of, or other Encumbrance upon any Acquired IP. Except as set forth on Schedule 7.2(f)(vii), no Acquired IP (i) was conceived, discovered, developed or otherwise made in connection with any research activities funded, in whole or in part, by the federal government of the United States or any agency thereof, (ii) is a “subject invention” as that term is described in 35 U.S.C. Section 201(e) or (iii) is otherwise subject to the provisions of the Bayh-Dole Act.

(viii)The execution and delivery of this Agreement and the Related Documents by Exicure do not, and the consummation of the Contemplated Transactions and compliance by Exicure with the provisions of this Agreement and any Related Document will not, conflict with, or result in any material breach of or default (with or without notice or lapse of time, or both) under, or give rise to a right of, or result in, termination, cancellation or acceleration of any obligation or to the loss of a benefit under, or result in the creation of any Encumbrance in or upon, any Acquired IP (other than Flashpoint’s ownership of Exicure’s right, title, and interest in and to the Acquired IP following the consummation of the Contemplated Transactions).

(ix)Exicure has not prior to the Closing Date assigned or licensed, to any Person, any Know-How, Patent or other Intellectual Property Right that is or could reasonably be expected to be necessary or useful for the research, development, manufacture, use or sale of any Compound or Product or the conduct of any Program, except as disclosed in Schedule 7.2(f)(ix).

(g)Regulatory. Schedule 7.2(g) accurately identifies all Regulatory Documentation and Regulatory Filings as of the Closing Date. Exicure owns all such Regulatory Documentation and Regulatory Filings. To the knowledge of Exicure, Exicure and its Affiliates have generated, prepared, maintained, and retained all Regulatory Documentation and Regulatory Filings that are required to be maintained or retained pursuant to and in accordance with good laboratory, manufacturing and clinical practice and in compliance with Applicable Law, and all such information is true and complete and accurate and what it purports to be. Neither Exicure nor any of its Affiliates, nor, to Exicure’s knowledge, any of its or their respective officers, employees, or agents, has made an untrue statement of material fact or fraudulent statement to the FDA or any other Regulatory Authority with respect to the development or manufacture of any Compound or Product, failed to disclose a material fact

required to be disclosed to the FDA or any other Regulatory Authority with respect to the development or manufacture of any Compound or Product, or committed an act, made a statement, or failed to make a statement with respect to the development or manufacture of any Compound or Product that could reasonably be expected to provide a basis for the FDA to invoke its policy respecting “Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities”, set forth in 56 Fed. Reg. 46191 (September 10, 1991) and any amendments thereto or any analogous laws or policies in the Territory. Neither Exicure nor any of its Affiliates have received any FDA Form 483, notice of adverse finding, safety notice, warning letter, untitled letter or other communication from the FDA or any other Regulatory Authority alleging or asserting noncompliance with Applicable Law with respect to any Compound or Product.

(h)Litigation. Except as set forth on Schedule 7.2(h), there is no Action to which Exicure or any Affiliate of Exicure is a party (either as plaintiff or defendant) or to which the Acquired Assets are subject that is pending, or, to Exicure’s knowledge, threatened in writing, that relates to any Program or the Exploitation of the Acquired Assets or that, if successful, could reasonably be expected to result in restraining, enjoining or otherwise preventing the completion by Exicure of the Contemplated Transactions, nor are there, to Exicure’s knowledge, any facts, circumstances or conditions on which any such Action would reasonably be expected to be brought in the future. There is no Action related to any Program or Exploitation of the Acquired Assets that (a) resulted in an order of any Governmental Authority against or settlement (whether or not such order or settlement was paid, in whole or in part, by an insurer of Exicure or other Third Party) or (b) resulted in any equitable relief or (c) relates to the Contemplated Transactions. There is no Action which Exicure presently intends to initiate relating to or involving any Program or the Exploitation of the Acquired Assets.

(i)Exicure Documents. Schedule 7.2(i) accurately identifies all Exicure Documents as of the Closing Date. Exicure is the sole owner of all Exicure Documents.

(j)Clinical Trials. Schedule 7.2(j) accurately identifies each and every clinical trial of any Compound or Product that was initiated prior to the Closing Date. Unless otherwise indicated, all such clinical trials have been completed or terminated and there are no further activities (including patient follow-up) contemplated or required with respect to any such clinical trial.

(k)No Debarment. Neither Exicure nor any of its Affiliates has been debarred, disqualified, suspended, or excluded, or is subject to debarment, disqualification, suspension, or exclusion, and neither Exicure nor any of its Affiliates has used or will use in any capacity, in connection with any services to be performed under this Agreement, any Person who has been debarred pursuant to 21 U.S.C. § 335a or any similar law or excluded under 42 U.S.C. § 1320a-7 or any similar law or regulation, or who has been convicted of any crime or engaged in any conduct that would reasonably be expected to result in debarment, disqualification, suspension, or exclusion.

(l)Good Laboratory Practice. To the knowledge of Exicure, Exicure and its Affiliates have at all times conducted, and have caused their contractors and consultants to conduct at all times, any and all pre-clinical and clinical studies related to any Program,

Compound or Product in accordance with good laboratory and clinical practice and in compliance with Applicable Law, as applicable and as appropriate to the given development stage.

(m)Safety Reporting. To the knowledge of Exicure, Exicure and its Affiliates are, and at all times have been, in compliance with all adverse event reporting requirements applicable to any Compound or Product. To the knowledge of Exicure and its Affiliates, Schedule 7.2(m) sets forth a complete and accurate list of all (i) adverse drug experience information; (ii) material events and matters concerning or affecting safety (including clinical holds) or lack of efficacy; and (iii) medical inquiries and complaints, in each case, relating to any Compound or Product. Neither Exicure nor any of its Affiliates has any knowledge of any scientific or technical facts or circumstances that would adversely affect the scientific, therapeutic, or commercial potential of any Compound or Product. Neither Exicure nor any of its Affiliates is aware of anything that could adversely affect the acceptance, or the subsequent approval, by any Regulatory Authority of any filing, application or request for Regulatory Approval with respect to any Compound or Product.

(n)Good Manufacturing Practice. To the knowledge of Exicure, Exicure and its Affiliates, and all contractors and consultants of any of the foregoing, have at all times conducted, all manufacturing activities with respect to Compounds and Products in accordance with good manufacturing practice and in compliance with all Applicable Laws.

(o)No Conflicts; Consents.

(i)The execution and delivery of this Agreement and the Related Documents and the performance by Exicure of its obligations hereunder or thereunder do not and will not conflict with, or result in any violation or breach of, or default (with or without notice or lapse of time, or both) under, or give rise to a right of, or result in, termination, cancellation or acceleration of any material obligation or to the loss of a benefit under, or result in the creation of any material Encumbrance in or upon the Acquired Assets under, Exicure’s Certificate of Incorporation and Bylaws or any Applicable Law applicable to Exicure or the Acquired Assets.

(ii)Exicure has not entered, and shall not enter into any Contract with any Third Party that is in conflict with the rights granted to Flashpoint under this Agreement, and Exicure has not taken and shall not take any action that would in any way prevent it from granting the rights granted to Flashpoint under this Agreement, or that would otherwise materially conflict with or adversely affect Flashpoint’s rights under this Agreement. Exicure’s performance and execution of this Agreement does not and will not result in a breach of any other Contract to which it is a party. As of the Closing Date, Exicure and its Affiliates are aware of no Action instituted by any Third Party that threatens the validity of this Agreement.

(iii)No consent, approval, order or authorization of, action by or in respect of, or registration, declaration or filing with, any Governmental Authority or Third Party is required by or with respect to Exicure or the Acquired Assets for, or in connection with, (i) the execution and delivery of this Agreement by Exicure, (ii) the transfer of the Acquired Assets to Flashpoint or (iii) the consummation of the Contemplated Transactions.

(p)No Undisclosed Liabilities. Except for the Assumed Liabilities, Exicure has no material liabilities related to the Acquired Assets that are not Retained Liabilities.

(q)Absence of Certain Changes. Since December 31, 2023, (i) no event, change, fact, condition or circumstance has occurred or arisen that has had, or would reasonably be expected to have, individually or in the aggregate, a material adverse effect on the Acquired Assets, and (ii) there has not been any material loss, destruction or damage affecting any Acquired Asset.

(r)Full Disclosure. To Exicure’s knowledge, all written data, results and other information disclosed to Flashpoint or its Affiliate at any time prior to the Closing Date by Exicure or its Affiliates relating to the Acquired Assets are true and accurate. Additionally, Exicure and its Affiliates have not failed prior to the Closing Date and will not fail to disclose to Flashpoint any material information known to Exicure or its Affiliates that relates to the Acquired Assets or that would be required to be disclosed in order to make the data, results, and other information relating to the Acquired Assets that have been disclosed not misleading.

(s)Certain Business Practices. None of Exicure, and to Exicure’s knowledge, Exicure’s employees or other Representatives (i) has used or is using any funds for any unlawful contributions, unlawful gifts, unlawful entertainment or other unlawful expenses; (ii) has made any direct or indirect unlawful payments to any foreign or domestic Government Official; (iii) has violated or is violating any Anti-Corruption Laws; (iv) has established or maintained, or is maintaining, any unlawful or unrecorded fund of monies or other properties; (v) has made, or is making, any false or fictitious entries on its accounting books and records; (vi) has made, or is making, any bribe, rebate, payoff, influence payment, kickback or other unlawful payment of any nature, or has paid, or is paying, any fee, commission or other payment that has not been properly recorded on its accounting books and records as required by the Anti-Corruption Laws; and (vii) has otherwise given or received anything of value to or from a Government Official, an intermediary for payment to any individual including Government Officials, any political party or customer for the purpose of obtaining or retaining business.

(t)Tax Matters. Exicure (i) has timely and properly paid all Taxes required to be paid that relate to the Acquired Assets or the Assumed Liabilities to the appropriate Governmental Authority (whether or not shown on any Tax Return) and no such Taxes are delinquent and (ii) has timely filed all Tax Returns required to be filed that relate in whole or in part to the Acquired Assets or the Assumed Liabilities. All such Tax Returns are true, complete and accurate in all material respects and were prepared in accordance with Applicable Laws. There are no liens for Taxes on any of the Acquired Assets except for Taxes not yet due and payable. There is no material audit, examination, investigation, contest, litigation, or other proceeding relating to Taxes pending or threatened in writing with respect to any of the Acquired Assets or Assumed Liabilities.

(u)Going Concern. (i) Immediately after giving effect to sale, conveyance, delivery, transfer and assignment of the Acquired Assets contemplated by this Agreement, Exicure shall: (a) be able to pay its debts as they become due; (b) own property that has a fair saleable value greater than the amounts required to pay its debts (including an amount of all

contingent liabilities based on a fair valuation); and (c) have adequate capital to carry on its business; (ii) in connection with the Contemplated Transactions, Exicure has not incurred, nor plans to incur, debts beyond its ability to pay as they become absolute and matured; (iii) the consummation of the Contemplated Transactions does not and will not constitute any transfer or incurrence of any obligation with intent to hinder, delay or defraud any present or future creditor of Exicure; and (iv) the Contemplated Transactions do not and will not constitute a fraudulent transfer, fraudulent conveyance or similar theory under applicable law (including, without limitation, the provisions of Section 548 of the U.S. Bankruptcy Code, the Uniform Voidable Transactions Act, the Uniform Fraudulent Conveyance Act, the Uniform Fraudulent Transfer Act and other similar laws).

(v)Brokers and other Advisors. No broker, investment banker, financial advisor or other Person is entitled to any broker’s finder’s financial advisory or similar fee or commission in connection with the Contemplated Transactions based upon arrangements made by or on behalf of Exicure.

(w)Inventor Letter. Exicure covenants to use commercially reasonable efforts to expeditiously deliver a letter to each of the Inventors in the form attached hereto as Annex F (each, an “Inventor Letter”) after the Closing Date.

7.3Pre-Closing Period. From the Effective Date until the Closing Date, Exicure shall not take any action (or fail to take any action) if such action (or inaction) could reasonably be expected to (a) materially and adversely affect the Acquired Assets or any rights purported to be transferred and granted to Flashpoint under the Acquired Assets or (b) materially increase liabilities to be assumed by Flashpoint under the Assumed Liabilities; provided that Exicure shall, at its sole expense, take the necessary measures to extend or renew the Acquired Contracts set to expire or terminate prior to the Closing Date, if requested by Flashpoint.

7.4Further Assurances. Each Party covenants to do and perform, and cause to be done and performed, all such further acts and things, and to execute and deliver all such other agreements, certificates, instruments and documents, as the other Party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the Contemplated Transactions. In addition to the foregoing, for a period of 180 days following the Closing Date, Exicure shall perform all acts reasonably requested by Flashpoint for the purpose of transferring and transitioning to Flashpoint all Know-How included in the Acquired Assets and providing to Flashpoint such other information as Flashpoint may reasonably request to enable Flashpoint and its Affiliates and Third Party service providers to Exploit the Acquired Assets.

7.5Disclaimers. EXCEPT AS OTHERWISE SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES, AND EACH PARTY HEREBY DISCLAIMS, ANY AND ALL REPRESENTATIONS AND WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, WITH RESPECT TO THE SUBJECT MATTER OF THIS AGREEMENT, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT AND ANY WARRANTY ARISING OUT OF PRIOR COURSE OF DEALING AND USAGE OF TRADE.

Article 8

Indemnification

8.1Indemnification by Flashpoint. Subject to Section 8.3, Flashpoint hereby agrees to indemnify, defend and hold harmless Exicure, its Affiliates, and all of their respective officers, directors, trustees, employees, and agents and their respective successors, heirs and assigns (collectively, the “Exicure Indemnitees”) from and against all liabilities, damages, expenses and/or loss, including reasonable legal expenses and attorneys’ fees (collectively, “Losses”), resulting from Third Party suits, claims, Actions, proceedings and demands (collectively, “Claims”) against an Exicure Indemnitee arising from (a) Flashpoint’s or its Affiliates’ or Licensees’ research, development, manufacturing, use, marketing or sale of any Compounds or Products or conduct of any Programs or Acquired Assets, in each case after the Closing Date; (b) any Assumed Liabilities; (c) the Northwestern Liabilities; or (d) Flashpoint’s or its Affiliate’s negligence, intentional misconduct, fraud or breach of any obligation, representation, warranty or covenant in this Agreement; provided, that, for purposes of clause (c), “Losses” shall exclude costs and expenses (including legal expenses and attorneys’ fees) relating to the Arbitration that have accrued or been paid through the Closing Date. The foregoing indemnity obligation shall not apply to the extent that any Claim arises from, is based on, or results from any activity or circumstance for which Exicure is obligated to indemnify the Flashpoint Indemnitees under Section 8.2.

8.2Indemnification by Exicure. Subject to Section 8.3, Exicure hereby agrees to indemnify, defend and hold harmless Flashpoint, its Affiliates, and all of their respective officers, directors, trustees, employees, and agents and their respective successors, heirs and assigns (collectively, the “Flashpoint Indemnitees”) from and against all Losses resulting from Claims against a Flashpoint Indemnitee arising from: (a) Exicure’s or its Affiliates’, contractors’ or Licensees’ research, development, manufacturing, use, marketing or sale of any Compound or Product or conduct of any Program or the Acquired Assets, in each case on or prior to the Closing Date, (b) any Retained Liabilities, including any breach by Exicure or its Affiliate of any obligation, representation, warranty or covenant in any Acquired Contract on or prior to the Closing Date, or (c) Exicure’s or its Affiliates’, contractors’ or licensees’ negligence, intentional misconduct, fraud, or breach of any obligation, representation, warranty or covenant in this Agreement. The foregoing indemnity obligation shall not apply to the extent that any Claim arises from, is based on, or results from any activity or circumstance for which Flashpoint is obligated to indemnify the Exicure Indemnitees under Section 8.1.

8.3Procedures.

(a)To be eligible to be indemnified as described in this Article 8, each Indemnitee seeking to be indemnified shall provide the indemnifying Party with prompt notice of any Claim (with a description of the claim and the nature and amount of any such loss) giving rise to the indemnification obligation pursuant to Section 8.1 or 8.2, as the case may be; provided, however, that the failure to give such notification or any deficiency in such notification

shall not affect the indemnification provided under Section 8.1 or 8.2 except to the extent that the indemnifying Party has been actually prejudiced as a result of such failure or deficiency.

(b)The indemnifying Party shall have the ability to control the defense of such claim (with the reasonable cooperation of Indemnitee(s)). Each Indemnitee shall have the right to retain its own counsel, at its own expense, or, if representation by the counsel of the indemnifying Party would be inappropriate due to actual or potential differing interests between such Indemnitee(s) and the indemnifying Party, then at the indemnifying Party’s expense. The cost of defending any Claim shall also be at the indemnifying Party’s expense if the indemnifying Party does not promptly assume defense of, and continue to diligently defend, such Claim. Neither the Indemnitee(s) nor the indemnifying Party shall settle or consent to the entry of any judgment with respect to any Claim for which indemnification is sought without the prior written consent of the other (not to be unreasonably withheld or delayed); provided however, that the indemnifying Party shall have the right to settle or compromise any claim for losses without such prior written consent if the settlement or compromise provides for a full and unconditional release of the Indemnitee(s) and is not materially prejudicial to any Indemnitee’s rights.

8.4Survival. Article 4 and the representations, warranties covenants and obligations contained in this Agreement shall survive the Closing; provided, that, except in the case of fraud or intentional misrepresentation (i) the representations and warranties set forth in Sections 7.2(a) and 7.2(b) shall survive until the date which is one hundred eighty (180) days after the expiration of the applicable statute of limitations, (ii) the remaining representations and warranties contained in this Agreement for a period of twenty-four (24) months from the Closing Date and (iii) any obligations pursuant to subparagraph (b) of Section 8.2, subparagraph (c) of Section 8.1, and any claims relating to Taxes shall survive for a period of six (6) years from the Closing Date. Notwithstanding the foregoing, the indemnification obligations set forth in this Article 8 shall not terminate with respect to any claims as to which the Indemnitee shall have delivered a notice of such claim to the indemnifying Party prior to the expiration of the applicable survival period.

8.5Sole and Exclusive Remedy. Each of the Parties acknowledges and agrees that, as between the Parties, except in the case of claims for equitable relief and claims and causes of action arising from fraud or intentional misrepresentation, its sole and exclusive remedy with respect to third party Claims shall be pursuant to the indemnification provisions set forth in this Article 8. Notwithstanding the foregoing or anything to the contrary in the remainder of this Agreement, Flashpoint may, at its election, set off, deduct or retain any amount due to any Flashpoint Indemnitees under this Article 8 against any payments Flashpoint may be obligated to make pursuant to this Agreement. Flashpoint will promptly notify Exicure in writing of any such offset, which notice shall indicate the amount so offset and the reason for such offset.

Article 9

Dispute Resolution

9.1Resolution by Executive Officers. The Parties recognize that disputes between the Parties as to certain matters may from time to time arise during the term of this Agreement which relate to either Party’s rights and/or obligations hereunder. It is the objective of the Parties

to establish procedures to facilitate the resolution of disputes arising under this Agreement in an expedient manner by mutual cooperation and without resort to litigation. To accomplish this objective, the Parties agree to follow the procedures set forth in this Section 9.1 to resolve any controversy or claim arising out of, relating to or in connection with any provision of this Agreement, if and when a dispute arises under this Agreement. With respect to all disputes arising between the Parties under this Agreement, including, without limitation, any alleged breach under this Agreement or any issue relating to the interpretation or application of this Agreement, if the Parties are unable to resolve such dispute within ten (10) days after such dispute is first identified by either Party in writing to the other, the Parties shall refer such dispute to the chief executive officer of Exicure and the chief executive officer of Flashpoint (collectively, the “Executive Officers”) for attempted resolution by good faith negotiations within thirty (30) days after such notice is received. If the Executive Officers are unable to resolve the dispute, controversy or claim through amicable internal resolution in accordance with this Section 9.1 within thirty (30) days after the matter was referred to them and either Party wishes to pursue the matter, such Party may submit such matter for resolution in accordance with Section 9.2.

9.2Arbitration.

(a)Any dispute between the Parties that is not resolved pursuant to Section 9.1, shall be finally settled by arbitration in accordance with the then-current rules of the American Arbitration Association’s Commercial Arbitration Rules (the “Rules”) by a single arbitrator selected in accordance with the Rules. The seat of arbitration shall be located in San Francisco, California, United States. The language to be used in the arbitral proceedings will be English. Any situation not expressly covered by this Agreement shall be decided in accordance with the Rules.

(b)The arbitrator shall issue a reasoned opinion following a full comprehensive hearing no later than twelve (12) months following the selection of the arbitrator as provided for in Section 9.2(a) unless the Parties jointly request an extension or the arbitrator determines in a reasoned decision that the interest of justice or the complexity of the case requires that such limit be extended.

(c)The arbitrator may only issue awards for monetary damages. Any such award shall be promptly paid in Dollars free of any tax, deduction or offset; and any costs, fees or taxes incident to enforcing the award shall, to the maximum extent permitted by Applicable Law, be charged against the Party resisting enforcement. Each Party agrees to abide by the award rendered in any arbitration conducted pursuant to this Section 9.2(c), and agrees that judgment may be entered in any court of competent jurisdiction and the Parties hereby consent to the jurisdiction of such court for purposes of enforcement of such award.

(d)Each Party shall bear its own legal fees and expenses arising out of the dispute resolution procedures described in this Section 9.2 and shall pay an equal share of the fees and expenses of the arbitrator.

(e)The arbitration proceeding shall be confidential and the arbitrator shall issue appropriate protective orders to safeguard each Party’s Confidential Information. Except as required by Applicable Law, no Party shall make (or instruct the arbitrator to make) any public announcement with respect to the proceedings or decision of the arbitrator without prior written consent of the other Party. The existence of any dispute submitted to arbitration, and the award, shall be kept in confidence by the Parties and the arbitrators, except (i) as required in connection with the enforcement of such award, (ii) as otherwise required by Applicable Law or required of a Party to fulfill a legal duty or protect or pursue a legal right, (iii) with the consent of both Parties, or (iv) where such information is already in the public domain other than as a result of a breach of this clause.

(f)Nothing contained in this Agreement shall deny either Party the right to seek injunctive or other equitable relief, including specific performance (but not monetary damages), from a court of competent jurisdiction in the context of a bona fide emergency or prospective irreparable harm, but limited solely to breaches of the provisions of Section 6.1, and such an Action may be filed and maintained notwithstanding any ongoing discussions between the Parties or any ongoing arbitration proceeding. In addition, nothing contained in this Agreement shall preclude Flashpoint from bringing an Action in any court of competent jurisdiction to resolve disputes with Third Parties pertaining to the validity, construction, scope, enforceability, infringement or other violations of Patents or other Intellectual Property Rights, and no such claim shall be subject to arbitration pursuant to this Section 9.2.

9.3Trial by Jury Waiver. TO THE EXTENT NOT PROHIBITED BY APPLICABLE LAW THAT CANNOT BE WAIVED, EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES, AND COVENANTS THAT IT WILL NOT ASSERT (WHETHER AS PLAINTIFF, DEFENDANT OR OTHERWISE), ANY RIGHT TO TRIAL BY JURY IN ANY FORUM IN RESPECT OF ANY ISSUE, CLAIM, DEMAND, ACTION OR CAUSE OF ACTION ARISING IN WHOLE OR IN PART UNDER, RELATED TO, BASED ON OR IN CONNECTION WITH THIS AGREEMENT, THE SUBJECT MATTER HEREOF OR ANY AGREEMENT CONTEMPLATED TO BE EXECUTED IN CONNECTION HEREWITH, OR ANY COURSE OF CONDUCT, COURSE OF DEALING, STATEMENTS (WHETHER VERBAL OR WRITTEN) OR ACTIONS OF ANY PARTY HERETO IN CONNECTION WITH ANY SUCH AGREEMENTS, WHETHER NOW EXISTING OR HEREAFTER ARISING AND WHETHER SOUNDING IN TORT OR CONTRACT OR OTHERWISE. ANY PARTY HERETO MAY FILE AN ORIGINAL COUNTERPART OR A COPY OF THIS SECTION 9.3 WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF EACH SUCH PARTY TO THE WAIVER OF ITS RIGHT TO TRIAL BY JURY.

Article 10

Conditions Precedent; Termination

10.1Conditions to the Obligations of Flashpoint. The obligation of Flashpoint to effect the Closing is subject to the satisfaction or waiver by Flashpoint, on or prior to the Closing Date, of the following conditions:

(a)Representations and Warranties. The representations and warranties of Exicure set forth in Section 7.2 shall be true and correct as of the Closing Date with the same effect as though made on and as of the Closing Date.

(b)Performance by Exicure. Exicure shall have performed and complied in all material respects with all of its covenants, agreements and obligations contained in this Agreement and required to be performed or complied with on or prior to the Closing Date.

(c)No Material Adverse Change. There shall not have occurred any material adverse change (i) on the business, assets, liabilities, financial condition or results of operations of Exicure, (ii) in the character or condition of any the Acquired Assets, or (iii) Exicure’s ability to consummate the Contemplated Transactions.

(d)No Actions. There shall not be pending or threatened in writing any Action brought by any Governmental Authority or any other Person seeking to restrain or prohibit the consummation of the Contemplated Transactions.

(e)No Injunctions or Restraints. No temporary restraining order, preliminary or permanent injunction or other order issued by any court of competent jurisdiction or other Applicable Law which has the effect of restraining, enjoining or otherwise preventing the consummation of the Contemplated Transactions shall be in effect.

10.2Conditions to the Obligations of Exicure. The obligation of Exicure to effect the Closing is subject to the satisfaction or waiver by Exicure, on or prior to the Closing Date, of the following conditions:

(a)Representations and Warranties. The representations and warranties of Flashpoint set forth in Section 7.1 shall be true and correct as of the Closing Date with the same effect as though made on and as of the Closing Date.

(b)Performance by Flashpoint. Flashpoint shall have performed and complied in all material respects with all of its covenants, agreements and obligations contained in this Agreement and required to be performed or complied with on or prior to the Closing Date.

(c)沒有任何禁令或限制沒有由任何有管轄權的法院或其他適用法律發佈的臨時禁令、初步或永久禁令或其他訂單生效，該禁令、禁令或其他訂單的作用是限制、禁止或以其他方式阻止擬議交易的完成。

10.3終止本協議可在結束日期之前的任何時間終止。

(a)截至2024年9月30日，「結束」之前未發生結束日期；但是，根據第10.3(a)節的規定，Flashpoint無法根據本協議終止的權利，如果違反了任何陳述、保證、契約或

本協議中規定的協議是否導致或致使截止日期前未能發生結案失敗;

(b)如果exicure在本協議中所作的任何陳述與保證在本協議簽署日起出現不準確，或在本協議簽署日之後的某個日期後出現不準確（好像是在該後續日期上並於該後續日期前作出），導致第10.1(a)節中規定的條件不滿足；或者本協議中的任何Exicure的約定或義務已經被違反，導致第10.1(b)節中規定的條件不滿足；或

(c)任何有管轄權法院或其他適用法律發出的臨時限制令、初步或永久禁令或其他限制、禁止或以其他方式阻止擬議交易完成的命令應當有效；但前提是，根據本第10.3(b)條款中的規定，如果任何一方對本協議中規定的任何陳述、保證、契約或協議的違約導致或導致了上述任何命令的頒佈、宣佈、執行或進入，則不得行使根據本條款終止本協議的權利。

(d)事實上，沒有任何法律要求禁止exicure出售，flashpoint擁有、經營或控制已收購資產或承擔的責任，也沒有使本協議或進行擬議交易的實施非法。

10.4終止的效力根據第10.3節，如果根據該協議和擬議交易終止，則Flashpoint應立即向exicure發出書面通知，該協議和擬議交易將終止，無需任何一方進一步行動；但是，前提是：(a) 任何一方不得免除因該方故意違反本協議任何條款而產生的任何責任；和(b) 本第10.4節和第11條不受此終止的影響，應繼續完整有效。

第11條

沒有僱傭合同。本方案中不存在構成員工和參與僱主之間的僱傭合同的內容。

11.1管轄法本協議應完全受特拉華州法律管轄，不考慮法律選擇原則或法規。聯合國國際貨物銷售合同公約不適用於本協議，並且明確地完全排除。

11.2通知根據本協議規定或允許的，所有通知應以書面形式發送，並通過掛號信或認證郵件郵寄至必須或被允許接收通知的簽署人，並通過以下地址發送電子郵件。所有通知應當被視爲在電子郵件確認或郵件交付確認收到時已發送。

所有通知均應寄往Flashpoint如下地址：

Flashpoint Therapeutics，Inc.
4145 Amaranta Ave

加利福尼亞州Palo Alto市94306
注意：亞當·馬戈林
電子郵件： adam@flashpoint.bio

抄送（這並不構成通知）：

Goodwin Procter LLP

馬歇爾街601號

加利福尼亞州雷德伍德市94063
注意：尊敬的Deepa Rich
郵箱： drich@goodwinlaw.com

所有板塊通知應如下地址寄送給exicure公司：

exicure公司
2430 North Halsted Street

芝加哥，IL 60614
收件人：安娜·楚卡婭娃
郵箱：achukaeva@exicuretx.com

抄送給（不構成通知）:

富利律師事務所
555 California Street

加利福尼亞州舊金山94109
注意：Kelly Boyd, Esq。
電子郵件：Kelly.boyd@foley.com

任何一方均可通過書面通知對方，指定一個新的地址或傳真號碼，隨後應將通知郵寄或傳真至該方的新地址或傳真號碼。

11.3不可抗力沒有一方應對無法控制的情況下導致的任何延遲或履行失敗負責，只要行使盡職盡責的能力無法阻止，包括火災、洪水、地震、颶風、禁運、短缺、流行病、大流行、檢疫、戰爭、戰爭行爲（無論是否宣戰）、恐怖主義行爲、暴動、騷亂、內亂、罷工、工會封鎖，或其他勞資糾紛（無論涉及無法履行方的勞動力或任何其他個人）、或天災。在每種情況下，該B類股東和/或該B類股東的家庭成員需獨立控制在此類帳戶、計劃或信託中持有的B類普通股實時；宣告免責的一方應盡商業上合理的努力克服相同的困難。受影響一方應儘快通知另一方有關不可抗力情況，並立即採取一切必要合理努力來消除該不可抗力情況。

11.4附加條款。本協議規定了與本協議所含內容相關的各方的整個協議和理解，併合並了雙方之間的所有先前討論和協議（包括先前的CDA），任何一方均不受任何陳述的約束，除非在本協議中明確聲明。本協議的附件和附表將通過引用並視爲本協議的一部分。本協議只能由雙方授權代表書面執行的書面文件進行修訂或修改。

11.5非放棄任何一方未就本協議的任何條款要求嚴格履行，或未行使本協議項下的任何權利均不影響該條款或權利的有效性，也不構成對該條款或權利的放棄，無論是整體放棄還是部分放棄，在該情況下或其他情況下均是如此。任何一方對某一特定條款或權利的放棄應以書面形式，應針對某一特定事項，並且如適用，應爲特定期限，並應由該方簽署。

11.6解僱費用如果本協議中的任何條款被認定爲無效、非法或不可執行，不影響其餘條款的有效性、合法性和可執行性，除非失效條款對各方的實質權利產生不利影響。在這種情況下，各方應盡最大努力用有效、合法和可執行的條款取代無效、非法或不可執行的條款，以實現本協議的目的。

11.7Assignment. Neither Party may assign or transfer this Agreement or any rights or obligations hereunder without the prior written consent of the other Party, except that Flashpoint may make such an assignment or transfer without Exicure’s consent to its Affiliate or to the successor to all or substantially all of the business of Flashpoint to which this Agreement relates (whether by merger, acquisition, consolidation, sale of assets, sale of a majority of the direct or indirect equity interests in Flashpoint or otherwise). Any permitted assignment shall be binding on the successors, heirs and assigns of the assigning Party. Any assignment or attempted assignment by a Party in violation of the terms of this Section 11.7 shall be null and void.

11.8Limitation of Liability.

(a)Without limiting Section 9.2(f), each Party’s liability under this Agreement shall apply only with respect to claims which, individually or in the aggregate, exceed Twenty Thousand US Dollars ($20,000.00) (the “Threshold”), but if the claims exceed in the aggregate the Threshold, the Party seeking damages is entitled to claim from the other Party the entire amount of all claims and not only the amount in excess of the Threshold.

(b)In no event shall the aggregate liability of each Party for the breach of any representation or warranty exceed: (a) with respect to breaches occurring during the period that is between the Closing Date and 12 months following the Closing Date, one hundred percent (100%) of the Consideration plus one hundred percent (100%) of the licensing fees actually received by Exicure pursuant to Section 4.3 hereof, (b) with respect to breaches occurring during

the period that is between 12 months and 24 months following the Closing Date, one hundred percent (100%) of the Consideration, (c) with respect to breaches occurring during the period that is between 24 months and 36 months following the Closing Date, eighty percent (80%) of the Consideration, and (d) with respect to breaches occurring during the period that is between 36 and 78 months following the Closing Date, fifty (50%) of the Consideration. Liability for breach of any representation or warranty herein shall terminate 78 months following the Closing Date. For purposes of this Section 11.8(b), a breach shall be deemed to have occurred as of the later to occur of (x) the date of the fact, event or circumstance giving rise to such breach and (y) the Closing Date.

(c)EXCEPT FOR FRAUD OR INTENTIONAL MISREPRESENTATION OR FOR BREACHES OF THE CONFIDENTIALITY OBLIGATIONS IN ARTICLE 6, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR INCIDENTAL, CONSEQUENTIAL, INDIRECT, PUNITIVE OR SPECIAL DAMAGES ARISING OUT OF OR RELATED TO THIS AGREEMENT, HOWEVER CAUSED, UNDER ANY THEORY OF LIABILITY, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

11.9Purchase Price Adjustments. To the extent permitted by Applicable Laws, any amounts payable under Article 8 or Article 9 shall be treated by Exicure and Flashpoint as adjustments to the purchase price paid for the Acquired Assets for U.S. federal income tax purposes.

11.10Performance by Affiliates. Flashpoint may discharge any obligations and exercise any right hereunder through any of its Affiliates. Flashpoint hereby guarantees the performance by its Affiliates of its obligations under this Agreement, and shall cause its Affiliates to comply with the provisions of this Agreement in connection with such performance. Any breach by Flashpoint’s Affiliate(s) of any of its obligations under this Agreement shall be deemed a breach by Flashpoint. Whenever this Agreement or any Related Document requires Exicure to take any action, such requirement shall be deemed to include an undertaking on the part of Exicure to its Affiliates to take such action.

11.11Relationship between the Parties. The Parties’ relationship, as established by this Agreement, is solely that of independent contractors. This Agreement does not create any partnership, joint venture or similar business relationship between the Parties. Neither Party is a legal Representative of the other Party, and neither party may assume or create any obligation, representation, warranty or guarantee, express or implied, on behalf of the other Party for any purpose whatsoever.

11.12No Third Party Rights. The provisions of this Agreement are for the exclusive benefit of the Parties, and no other Person shall have any right or claim against either Party by reason of these provisions or be entitled to enforce any of these provisions against either Party.

11.13Headings; Interpretation. The headings of clauses contained in this Agreement preceding the text of the sections, subsections and paragraphs hereof are inserted solely for convenience and ease of reference only and shall not constitute any part of this Agreement, or

have any effect on its interpretation or construction. All references in this Agreement to the singular shall include the plural where applicable. The term “including” or “includes” as used in this Agreement means including, without limiting the generality of any description preceding such term, and the word “or” has the inclusive meaning represented by the phrase “and/or.” Unless otherwise specified, references in this Agreement to any section shall include all subsections and paragraphs in such Section and references in this Agreement to any subsection shall include all paragraphs in such subsection. All references to days in this Agreement shall mean calendar days, unless otherwise specified. Ambiguities and uncertainties in this Agreement, if any, shall not be interpreted against either Party, irrespective of which Party may be deemed to have caused the ambiguity or uncertainty to exist.

11.14English Language. All notices required or permitted to be given hereunder, and all written, electronic, oral or other communications between the Parties regarding this Agreement shall be in the English language. This Agreement was prepared in the English language, which language shall govern the interpretation of, and any dispute regarding, the terms of this Agreement. In the event of any inconsistency or conflict between the English version of this Agreement and any translation of this Agreement into any other language, the English version shall control.

11.15Counterparts; Email or Facsimile Delivery. This Agreement may be executed in one or more counterparts, each of which shall be an original and all of which shall constitute together the same document. This Agreement may be executed via electronic signature, such as DocuSign or similar. Executed counterparts of this Agreement may be delivered by facsimile transmission or by delivery of a scanned counterpart in portable document format (PDF) by e-mail, in either case with delivery confirmed. On such confirmed delivery, facsimile or PDF signatures shall be deemed to have the same force and effect as if the manually signed counterpart had been delivered to the other Party in person.

[signature page to follow]

In Witness Whereof, the Parties hereto have duly executed this Asset Purchase Agreement as of the Effective Date.


Flashpoint Therapeutics, Inc. Name: Title:			Exicure, Inc. Name: Title:

Signature Page to Asset Purchase Agreement

Schedules

Schedule 1.21: Cavrotolimod Structure

Schedule 1.33: Excluded Contracts

Schedule 1.69: Programs and Related Compounds and Products

Schedule 2.1: Excluded Assets

Schedule 2.1(a): Acquired Contracts

Schedule 2.6: Transfer Schedule

Schedule 7.2(d): Contracts

Schedule 7.2(f)(i): Exicure Registered IP and Transferred Know-How

Schedule 7.2(f)(iv): Claims

Schedule 7.2(f)(v): IP Contracts

Schedule 7.2(f)(vii): Northwestern Patents

Schedule 7.2(f)(ix): Prior Licenses and Assignments

Schedule 7.2(g): Regulatory Documentation and Regulatory Filings

Schedule 7.2(h): Litigation

Schedule 7.2(i): Exicure Documents

Schedule 7.2(j): Clinical Trials

Schedule 7.2(m): Safety Reporting

Schedule 7.2(o): No Conflicts; Consents

Annex A: Assignment and Assumption Agreement

Annex B: Bill of Sale

Annex C: Exicure IND Letter

Annex D: Flashpoint IND Letter

Annex E: Patent Assignment Agreement

Annex F: Form of Inventor Letter